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ABSTRACT 
 
 In the present study, we investigated the involvement of Chmp1 (Chromatin Modifying 
Protein 1/Charged Multivesicular body Protein 1) in the development of mouse 
pancreatic acinar tumor cell line. CRL 2151 cell line was transfected with Chmp1/CS2 
vector to compare growth, morphology and expression of Chmp1, p53 and pp53 (ser 
37) with control-transfected cells. CRL 2151 cells were treated with all-trans retinoic 
acid (ATRA) to compare growth, morphology and expression of Chmp1 and p53 with 
control-treated cells. Strabismus was used as control. Results showed inhibition of 
growth but no morphological change in transfected cells. Western blot analysis showed 
that Chmp1 transfection upregulated the expression of p53, pp53 and Stbm temporarily. 
Treatment of cells with ATRA did not inhibit growth or show morphological change. 
However, Western blot analysis demonstrated the upregulation of Chmp1, p53 and 
Stbm proteins. Microarray analysis of samples transfected with Chmp1 or treated with 
retinoic acid was done to determine if the same set of genes will be regulated. The pro-
apoptotic genes Bad and Bak are among the genes up-regulated. Cell division cycle 
protein, Cdca7, was among the genes down-regulated. Results from Western blot 
analysis confirmed the expression of Bad and Bak genes. Taken together, these results 
suggest that Chmp1 functions in the suppression of pancreatic tumor by the retinoic 
acid signaling pathway. 
Key Words:  CRL 2151, Chmp1, Stbm, p53, Bad, Bak, Cdca7, ATRA.        
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 CHAPTER 1 
 
INTRODUCTION 
 
Chmp1 (Chromatin Modifying Protein 1/Charged Multivesicular body Protein 1) is a 
novel protein found to be widely conserved across eukaryotes [1, 2]. It is localized in the 
nucleus as well as in the cytoplasm.  It is found in the interphase nuclear matrix and 
mitotic chromosome scaffold affecting chromatin structure and cell cycle progression [2-
4]. In the cytoplasm, it is involved in protein sorting to the multivesicular body [1, 4-7]. 
Chmp1 therefore plays a dual function of nuclear gene regulation and membrane 
trafficking.  
Very few studies have so far been done on Chmp1. One of the studies reported 
that Chmp1 localizes to early and late endosomes in HEK 293 (human embryonic 
kidney) and COS7 (African green monkey kidney) cell lines [1]. This study further 
showed that it interacts with SKD1/VPS4 (vacuolar protein sorting 4b) in sorting proteins 
into multivesicular bodies. Another investigation by Stauffer et al, (2001) identified 
Chmp1 as a binding partner of Pcl (PcG polycomblike) proteins in HEK 293 cell line. 
The PcG (polycomb group) are proteins involved in gene silencing. In addition, they 
reported that Chmp1 affects nuclear structure by increasing nuclear DNA concentration 
through chromatin condensation. It was shown to also affect DNA replication by 
arresting cells in S-phase of the cell cycle.  
 A closely related protein family of Chmp1 (Chmp1b) was studied by Reid et al, 
(2004). They identified Chmp1b as a binding partner of Spastin in COS7 and PC12 
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(Pheochromocytoma) cell lines. Spastin is a protein involved in hereditary spastic 
paraplegia (HSP), a neurological disorder characterized by progressive weakness and 
stiffness of the leg. They found that the expression of Chmp1b prevented the 
development of the abnormal phenotype associated with the expression of mutated 
spastin, suggesting a regulatory role for Chmp1b. Furthermore, they suggested that 
Chmp1b interacted with Spastin to play a role in membrane trafficking. Interestingly, a 
homolog of Chmp1 was identified in plant. This homolog, SAL1 (supernumerary 
aleurone layers 1), was studied in maize by Shen et al, (2003). They found SAL1 to be 
involved in regulating the formation of aleurone cell layer in maize grains. Failure to 
target internalized membranes to lytic vacuoles in grain with mutated sal1 resulted into 
more layers of aleurone cells in defective maize endosperm. These results suggest that 
SAL1 may be involved in membrane trafficking and the lack of this function may 
contribute to abnormal growth.    
Even though Chmp1 has been implicated in cell cycle progression, chromatin 
structure, gene silencing and membrane trafficking, its function in vertebrate 
development and in tumor formation is not yet known. 
  Our lab identified Chmp1 as one of Strabismus (Stbm) binding proteins from 
yeast two-hybrid screen. Strabismus is known to function in the Planar Cell Polarity 
(PCP) signaling pathway, modulating convergent extension movement in zebrafish [8]. 
Mis-expression of Chmp1 produced convergent extension movement defects in 
zebrafish similar to its binding partner, Stbm [Park et al, in preparation]. However unlike 
Stbm, Chmp1 mis-regulation (either by microinjecting embryo with Chmp1 mRNA or 
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Morpholino) induced hyperplasia (Figure 1), an abnormal cell growth, in zebrafish 
indicating that Chmp1 may function in tumorigenesis [Park et al, in preparation]. 
 
 
 
Figure 1: Induction of hyperplasia in zebrafish by Chmp1. Embryo was microinjected with Chmp1 mRNA, 
mis-regulation of Chmp1 induced abnormal growth. The embryos on the top are zebrafish at 2 days old; 
the images on the bottom are the same fish at 2½ days (Courtesy of Dr. Park’s lab). 
 
 
 To test this hypothesis, a human cancer profiling array from CLONTECH cancer 
Profiling Array II was screened to measure Chmp1 mRNA level. Also, a human cancer 
tissue array was screened to quantify Chmp1 protein level. Results obtained from the 
profiling array showed differential expression of Chmp1 between the various tumors and 
 
B 
C 
C
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their corresponding normal tissues. The pancreas showed the greatest differential 
expression between the tumors and their normal tissues (Figure 2).  
 
 
 
 
 
 
 
 
Figure 2: Cancer profiling array of cDNAs from various pancreatic tumors and their corresponding normal 
tissues. The left shows control Ubiquitin mRNA expression from various normal (N) and pancreatic tumor 
(T) samples. The array on the right is the same array showing Chmp1 mRNA level. The graph is a 
densitometric analysis of the results. This shows the dramatic repression of Chmp1 in pancreatic tumor 
(Courtesy of Dr Park’s lab). 
 
 
Among the pancreatic cancer tissues investigated, pancreatic acinar tumor is the 
only tumor which showed almost no expression of Chmp1 protein. Chmp1 protein 
expression within the pancreatic acinar tumor cells was greatly reduced even though its 
expression in the connective tissue cells was not reduced (Figure 3).   
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Figure 3:  Chmp1 antibody staining. Normal and tumor cells of the pancreas were immunostained with 
Chmp1 antibody. Arrows point to Chmp1 protein (dark brown stain) within the nucleus of the cells. Chmp1 
protein expression within the pancreatic acinar cells (right) is greatly reduced even though its expression 
in the connective tissue cells is not reduced (Courtesy of Dr. Park’s lab). 
 
On the basis of these results, we decided to investigate the role that Chmp1 may 
play in the development of pancreatic acinar tumors. Our lab is the first to investigate 
the involvement of Chmp1 in convergent extension movement and the induction of 
hyperplasia in vertebrate development. It is also the first to investigate the expression of 
Chmp1 during cancer development.   
acinar cells 
connective tissue 
pancreas normal tissue                                   pancreas cancer tissue 
acinar cells 
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Retinoids are natural and synthetic derivatives of vitamin A (retinol). They exert 
dramatic effects on cell death and differentiation in human tumor cells, and in vertebrate 
embryogenesis; modulating differentiation, proliferation and apoptosis in both normal 
and neoplastic tissues [9-15]. Several investigators have demonstrated that all-trans 
retinoic acid (ATRA) inhibits growth of pancreatic cancer cells both in vivo and in vitro 
[9, 13, 14, 16, 17]. This inhibition is thought to occur in part through the p53, a tumor 
suppressor, pathway [18].  
Pancreatic cancer is one of the rarest cancers and yet it is the fifth leading cause 
of cancer death in the United States, with an annual of  about 28,200 diagnoses and 
death [19-21]. The mortality rate is the highest among cancer types, in part because of 
the asymptomatic nature of the disease in early stages [21]. It affects men twice as 
frequently as women and is more likely to develop after the age of 40 [22]. Pancreatic 
cancer risks increase with chronic pancreatitis, diabetes mellitus, genetic factors (more 
common in African Americans than Caucasians), smoking, excess alcohol consumption, 
high-fat diets, and exposure to industrial chemicals such as urea, naphthalene or 
benzidine. Symptoms include weight loss, abdominal pain, and nausea, loss of appetite, 
itching, jaundice, and constipation. Because its symptoms mimic many other common 
health problems [22], it often goes undetected until it is too late to treat effectively. 
Pancreatic exocrine tumors are more common than the tumors from the 
endocrine. The majority of the exocrine tumors are adenocarcinomas, and nearly all of 
these are ductal adenocarcinomas. Pancreatic acinar cell carcinomas are rare 
neoplasms of the exocrine pancreas, comprising less than 1% of primary pancreatic 
tumors[23, 24]. They are distinct from the more common pancreatic ductal 
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adenocarcinomas.   The prognosis in adults is poor, with the majority of patients showing 
evidence of metastatic disease either at or subsequent to diagnosis [23, 25-28] ; and a 
reported mean survival of 18 months[23, 29, 30]. 
Pancreatic cancer is the only cancer with a diagnosis rate less than the mortality 
rate. More studies are therefore needed to better understand and address the cellular 
mechanisms and pathways by which this cancer develops. In the present investigation, 
we hypothesized that Chmp1 may function through retinoic acid signaling to inhibit cell 
growth by activating p53 [18].  
 
PURPOSE 
Our long term goal is to identify the potential pathways by which Chmp1 may function in 
pancreatic tumors. The first purpose was to determine how Chmp1 over-expression or 
gain of function through transfection may affect the growth of CRL2151, a pancreatic 
acinar tumor cell line. Morphology of cells was observed under the microscope and the 
number was counted. Based on the report from several investigators that retinoic acid 
inhibits growth of pancreatic cancer cells, we chose to treat CRL2151 cells with ATRA. 
The second purpose was to investigate growth inhibition, morphological changes and 
expression level of Chmp1, p53 and Stbm in CRL2151 cells after treatment with ATRA.  
We chose p53 on the basis of report of studies that indicates p53 to be expressed 
during cancer growth inhibition and its stability by phosphorylated p53 (pp53). Stbm was 
chosen as a control on the basis of it being a binding partner of Chmp1 in our previous 
investigation. The third purpose was to determine if Chmp1 gain of function or over 
expression would induce the up-regulation of p53 in CRL2151 cells. Fourthly, we set out 
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to confirm that Chmp1 functions through retinoic acid by activating p53. In this case we 
carried out microarray analysis of samples transfected with Chmp1 or treated with 
retinoic acid to determine if the same set of genes will be regulated.  The rationale for 
this research was that if the function of Chmp1 in pancreatic tumor is known, Chmp1 
may serve as a pharmacological target protein for treating pancreatic tumors.  
 
SPECIFIC AIMS  
The objective of this study was to determine the role of Chmp1 during the development 
of pancreatic acinar tumor. The hypothesis is that Chmp1 may function through retinoic 
acid signaling to inhibit cell growth by activating p53. In this study, we determine the 
effect of exogenous Chmp1 and ATRA on growth, morphology and expression of 
Chmp1, p53, pp53 and Stbm of CRL2151 cell line. We also determine the genes 
expressed by these two treatments. 
 
Specific Aim 1:  
To determine the effect of Chmp1 on the growth and morphology of CRL2151. In 
this case we transfected cells with Chmp1/CS2 vector and CS2 vector (control) 
for 1, 2, 3 and 4 days. Transfection with Stbm/CS2 vector also served as control. 
Photos of cells were taken, followed by cell counting and statistical analysis of 
cell numbers.  
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Hypothesis:  
We hypothesized that Chmp1 would induce a decrease in cell growth and cause 
morphologyical changes. 
 
Specific Aim 2: 
To determine the effect of ATRA on cell growth, morphology and the expression 
of Chmp1, p53 and Stbm in CRL2151 cells. Cells were treated with ATRA in 
Dimethyl Sulfoxide (DMSO) for 1, 2, 3 and 4 days.   Photos of cells were taken. 
Cells were trypsinized for cell count and lysed for Western blot on days 1, 2, 3 
and 4. Cell numbers were statistically analysed and alterations in the expression 
of Chmp1, p53 and Stbm were evaluated by densitometry method. 
 
Hypothesis: 
We hypothesized that ATRA will induce a decrease in cell growth and cause 
morphological changes in cells, with a corresponding increase in the expression 
of Chmp1 accompanied by increase in the expression of p53. 
 
Specific Aim 3: 
To determine the level of expression of Chmp1, p53, pp53 and Stbm in CRL2151 
cells transfected with Chmp1. Cells were transfected with Chmp1/CS2 and CS2 
vectors for 1, 2 and 3 days. Transfection of cells with Stbm/CS2 vector also 
served as control. Cells were trypsinized and lysed for Western blot. Alterations 
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in the expression of Chmp1, p53, pp53 and Stbm were evaluated by 
densitometry. 
 
Hypothesis: 
Our hypothesis was that the level of Chmp1 expression will increase with an 
accompanied increase in p53 and pp53 expression. 
 
Specific Aim 4: 
To determine that Chmp1 functions through retinoic acid by activating p53. In this 
case we expect that the same genes will be up or down regulated when 
CRL2151 cells are transfected with Chmp1 or treated with ATRA. To examine 
this possibility, we treated cells with ATRA and also transfected cells with 
Chmp1.  Cells were trypsinized and total cellular RNA was prepared using Tris 
Reagent. The gene expression level was determined by microarray analysis. 
Gene expression was confirmed by Western-blot. Expression of proteins was 
evaluated by densitometry. 
 
Hypothesis:  
We hypothesized that similar genes will be expressed when CRL2151 cells are 
treated with ATRA and transfected with Chmp1. 
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CHAPTER 2 
 
REVIEW OF THE LITERATURE 
 
INTRODUCTION 
This chapter presents a review of the relevant literatures concerning the present study. 
Specifically, the following areas will be addressed: 1) the potential functions of Chmp1 
and 2) the role of retinoids and their inhibition in the growth of cancers. 
 
The potential functions of Chmp1  
Chmp1 is a novel protein and a member of the Chmp protein family. It is known to 
contain a predicted bipartite nuclear localization signal. Also, it is reported to distribute to 
the nuclear matrix and to the cytoplasm [2]. In the nucleus, Chmp1 is localized in the 
nuclear matrix of HeLa (human epithelial carcinoma) cells where it affects chromatin 
structure and cell-cycle progression [2]. Chmp1 also functions as a member of a newly 
defined family of vesicle trafficking proteins in the cytoplasm in yeast [1, 4-7]. 
A zebrafish protein was identified from yeast two-hybrid screen, and named as 
SAP7 (Strabismus Associated Protein 7) in our lab. This protein was found to be a 
homolog of human Chmp1. The interaction between Chmp1 and Strabismus (Stbm) has 
also been confirmed by co-immunoprecipitation in our lab. Strabismus is involved in 
convergent extension movements in vertebrate [8, 31, 32].  Chmp1 also functioned in 
embryo development similar to Strabismus, and it induced hyperplasia when mis-
regulated in zebrafish [Park et. al., in preparation] (Figure 1). 
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Several investigators have reported that the Chmp family of proteins are 
components of endosomal sorting complex required for transport-III (ESCRT-III)[3, 4, 7, 
33, 34]. ESCRT-III is a membrane-associated protein complex that mediate the sorting 
of cargoes to the multivesicular body. This is why Chmp are referred to as Charged 
Multivesicular body Proteins, in addition to being called Chromatin Modifying Proteins. 
The Chmp proteins were originally identified in yeast genetic screens[35, 36]. 
Subsequent studies have identified at least one human homolog for each protein[37], 
indicating that they are conserved across eukaryotes. These proteins are recruited to 
sites of multivesicular body protein sorting and vesicle formation[34].  
 Proteins targeted for lysosomal degradation are sorted into vesicles that bud into 
late endosomal compartments called multivesicular bodies (MVB). Once formed, 
multivesicular bodies can undergo several different fates. They may either serve as 
long-term storage compartments, fusing with lysosomes to deliver the internal vesicles 
and their contents for degradation. Or they may fuse with the plasma membrane to 
release the vesicles as extracellular “exosomes.”  MVB function in a number of 
important biological processes, including receptor down-regulation, antigen 
presentation, intercellular communication, and development[35, 38-40]. Vesicle 
trafficking therefore provides communication and transport between membrane-bound 
compartments involved in biosynthesis, degradation and cell surface signaling. Also, a 
number of enveloped RNA viruses, including HIV-1, are reported to usurp cellular 
proteins involved in MVB biogenesis to facilitate virus budding [37, 41]. 
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  Chmp1, like most other members of the Chmp family, is implicated in 
multivesicular body (MVB) formation. In this process it is reported to localize to early  
and late endosomes physically interacting with SKD1/VPS4 (vacuolar protein sorting 
4b), a highly conserved protein directly linked to multivesicular body sorting in both 
human and yeast[33, 42-45].  
Investigation by Stauffer, et al., (2001) revealed other important functions of 
Chmp1. They reported that Chmp1 has potent affects on nuclear structure by increasing 
nuclear DNA concentration through chromatin condensation. Also Chmp1 affects DNA 
replication by arresting cells in S-phase of the cell cycle. Furthermore they identified 
Chmp1 as a partner of the PcG protein polycomblike (Pcl). The PcG (polycomb group) 
consists of a large, structurally diverse set of nuclear proteins, which functions both to 
select target genes and regulate their transcription in epigenetic modifications. The PcG 
proteins are involved in maintenance of the silenced state of several developmentally 
regulated genes.  When Chmp1 is over-expressed, it is reported to encapsulate proteins 
in the Polycomb complex and localize them to visibly condensed chromatin, suggesting 
that Chmp1 may function with PcG in gene silencing [2].  
Closely related family of Chmp1, Chmp1b, is identified as a binding partner of 
Spastin in COS7(African green monkey kidney) and PC12(Pheochromocytoma) cell 
lines [3]. Mutations in spastin are responsible for hereditary spastic paraplegia (HSP), a 
group of inherited disorders characterized by progressive weakness and stiffness of the 
legs. Expression of Chmp1b prevented the development of this abnormal phenotype 
associated with the expression of mutated spastin, suggesting a regulatory role for 
Chmp1b. Also, Chmp1b interacted with Spastin to play a role in membrane trafficking. 
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Another homolog of Chmp1, SAL1 (supernumerary aleurone layers 1), is identified in 
maize [6]. SAL1 protein is involved in the regulation of aleurone cell (a component of the 
endosperm in cereal grains) formation in maize grains. The failure to target internalized 
membranes to lytic vacuoles in grain carrying mutated sal1 caused more layers of 
aleurone cells in defective maize endosperm, suggesting that SAL1 May be involved in 
membrane trafficking. 
Overall, reports from the few studies on Chmp1 suggest that Chmp1 may 
function in several pathways which involve gene regulation and membrane trafficking. 
Even though Chmp1 has been implicated in cell cycle progression, chromatin structure, 
gene silencing and membrane trafficking, the function of Chmp1 in vertebrate 
development and in tumor formation has not been studied. 
 
Summary 
Chmp1 is a novel protein and a member of the Chmp protein family. Chmp1 is 
conserved across eukaryotes. It functions in gene expression and silencing. It also 
functions in cell-cycle progression. Chmp1 induces hyperplasia in zebrafish and is 
involved in convergent extension movement in embryogenesis. It is involved in protein 
sorting to the multivesicular body. Its function in tumors is yet unknown.  
 
Retinoids and their inhibition in the growth of cancers 
 
Retinoids belong to a class of molecules that are structurally related to vitamin A. They 
have potent anti-proliferative and differentiating effects on a variety of normal and 
neoplastic tissues [9, 10, 12-15]. They also play a crucial role in embryogenic 
 15 
 
 
development [10, 12, 46-48]. They are therapeutically effective in the treatment of some 
cancers, skin disorders such as acne, psoriasis and photoaging, and have the potential 
for protecting certain cells from particular injury [49]. Retinoids have the ability to arrest 
growth in carcinoma cells, melanoma, lymphoma, neuroblastoma, and embryonic stem 
cells [50].  The potential role of different types of retinoids for pancreatic cancer in vitro 
and in vivo has been reported [9, 16, 51, 52],  with several investigators demonstrating 
that all-trans retinoic acid (ATRA) inhibits growth of human pancreatic-cancer cells in 
vitro and in vivo [9, 16].  
Cancers of the pancreas can be grouped according to where in the pancreas the 
cancer is or according to the type of cell the cancer has originated from. It can occur in 
the head, body or tail of the pancreas. The vast majority of cancers of the pancreas are 
the exocrine type, and most of these are adenocarcinomas, nearly all are ductal 
adenocarcinomas. The ducts carry pancreatic digestive juices to the main pancreatic 
duct and the duodenum. The rarer types of exocrine pancreatic cancers are cystic 
tumors, cancer of the acinar cells and sarcomas. The acinar cells are the cells at the 
ends of the ducts that produce the pancreatic juices.  
Most of the effects of retinoids in pancreatic cancers are due to the activation of 
the retinoic acid receptors. This triggers transcriptional events that lead either to 
transcriptional activation or repression of retinoid-controlled genes. These biological 
effects of retinoic acid (RA) are mediated by nuclear retinoic acid receptors (RARs) and 
retinoid X receptors (RXRs). Each receptor family consists of three receptor subtypes ( , 
, ) encoded by independent genes [50, 53, 54]. Modulation of gene expression occurs 
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through binding of ligand-activated RAR/RXR to retinoid responsive elements located in 
the regulatory regions of target genes [47, 55-62].  
The inhibition of cancer cells by retinoids is thought to occur through the p53 
pathway [18]. Inhibition  may occur by means of G1-phase cell-cycle arrest resulting 
from the prevention of RB (retinoblastoma) phosphorylation and the up-regulation of 
p21 and p27, as well as the induction of apoptosis [17]. 
 The p53 protein is a tumor-surpressor of cells that prevents their entry into the 
route to carcinogenesis[63]. It is a multifunctional protein that can modulate genes 
involved  in the control of cell growth and apoptosis [64]. In response to cellular stress 
such as DNA damage, hypoxia and oncogenic signals, p53 functions in cell cycle 
progression checkpoints arrests[63, 65]. The protein p53 induces apoptosis (a type of 
programmed cell death) by target gene regulation and by translocating to the 
mitochondria to promote the release of cytochrome c [65, 66]. Commitment of cells to 
apoptosis is controlled largely by the interaction between members of the Bcl-2 protein 
family. Activated p53 tansactivates pro-apoptotic genes such as Bad and Bak [67]. Bad 
and Bak in turn trigger apoptosis when they bind to Bcl-2 or its homologs and block their 
antiapoptotic activity[67-71].  
Several investigations on the effect of retinoids on pancreatic tumor cells have 
been done.  It is not known if Chmp1 expression occurs when pancreatic tumor cells are 
treated with retinoids. 
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Summary 
Retinoids modulate cellular proliferation and differentiation in a variety of tissues of the 
adult organism as well as during embryogenesis and development. Studies have been 
done to investigate RA-mediated growth inhibition and apoptosis on some pancreatic 
cancer cells. However no study has investigated whether Chmp1 functions through RA 
signaling. 
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CHAPTER 3 
 
CHMP1 IS IMPLICATED IN THE DEVELOPMENT OF PANCREATIC TUMOR VIA  
THE RETINOIC ACID SIGNALING PATHWAY 
 
J. Akinsete and M. Park 
Department of Biological sciences and Department of Biochemistry, 
Marshall University 
 
ABSTRACT 
In the present study, we investigated the involvement of Chmp1 in the development of 
mouse pancreatic acinar tumor cell line. CRL 2151 cell line was transfected with 
Chmp1/CS2 vector to compare growth, morphology and expression of Chmp1, p53 and 
pp53 (ser 37) with control-transfected cells. CRL 2151 cells were treated with all-trans 
retinoic acid (ATRA) to compare growth, morphology and expression of Chmp1 and p53 
with control- treated cells. Strabismus was used as control. Results showed inhibition of 
growth but no morphological change in transfected cells. Western blot analysis showed 
that Chmp1 transfection upregulated the expression of p53, pp53 and Stbm temporarily. 
Treatment of cells with ATRA did not inhibit growth or show morphological change. 
However, Western blot analysis demonstrated the upregulation of Chmp1, p53 and 
Stbm proteins. Microarray analysis of samples transfected with Chmp1 or treated with 
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retinoic acid was done to determine if the same set of genes will be regulated. The pro-
apoptotic genes Bad and Bak are among the genes up-regulated. Cell division cycle 
protein, Cdca7, was among the genes down-regulated. Results from Western blot 
analysis confirmed the expression of Bad and Bak genes. Taken together, these results 
suggest that Chmp1 functions in the suppression of pancreatic tumor by the retinoic 
acid signaling pathway. 
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INTRODUCTION 
Pancreatic cancer is the fifth leading cause of cancer death in North America [72]. It is 
second only to colon cancer as a cause of death from gastrointestinal malignancy, and 
affects men twice as frequently as women with more possibility of developing after the 
age of 40 [22]. It is the only cancer with a diagnosis rate less than the mortality rate.  
With resection surgery, radiotherapy and conventional chemotherapy, the prognosis of 
advanced pancreatic cancer has not recorded any significant improvement over the last 
30 years, showing a 5-year survival rate of less than 5% [73]. However, several 
investigators have demonstrated that all-trans retinoic acid (ATRA) inhibits growth of 
human pancreatic-cancer cells in vitro and in vivo [9, 16].  
Retinoids are vitamin A derivatives, used effectively in the therapeutic treatment 
of some cancers[9, 49]. Their effects on both normal and cancer cells include 
modulations of differentiation, proliferation and apoptosis [10, 15]. RARs and RXRs are 
the nuclear receptors of retinoids. They function as transcription factors modulating the 
activity of several target genes [10, 55].  
 Albrechtsson et al., (2002) studied the expression of retinoic acid receptors 
(RAR) in pancreatic cancer cells and the effect of three different retinoids on the cell 
number in vitro. They reported a decrease in cell number to high concentration of RA 
and the expression of two or more subtypes of RAR in all pancreatic cell lines 
investigated. Bold et al., (1996) studied the effect of retinoic acid on the growth of both 
exocrine and endocrine pancreatic cancer cell lines. The growth of all tumor cell lines 
was inhibited by retinoic acid. In their own investigation, Rosewicz et al., (1995) found a 
 21 
 
 
time-and dose-dependent growth inhibition in pancreatic carcinoma cells resulting from 
retinoid treatment. There was expression of retinoid receptors and induction of 
differentiation in cells. Also the effect of TAC-101, a novel retinoid, was studied on 4 
human pancreatic-cancer cell lines by Fujimoto et al., (1999). It was reported that TAC-
101 inhibits the growth of certain pancreatic cancer cells by means of G1-phase cell 
cycle arrest due to the reduction of RB phosphorylation and the up-regulation of p21 
and p27. It also induces apoptosis. 
Another investigation involving retinoic acid-responsive protein was carried out 
by Kaiser et al., (1999). They identified the kinesin-related novel protein HsEg5 as an 
all-trans-retinoic acid (ATRA)-responsive gene in pancreatic carcinoma cells, mediating 
growth inhibition.  The protein HsEg5 was found to play an essential role in spindle 
assembly and spindle function, resulting in a delayed progression through mitosis. 
Even though various studies have demonstrated that retinoids inhibit the growth 
of pancreatic cancer cells, there is need for more studies that will provide a conceptual 
framework to identify novel therapeutic target proteins.   
Chmp1 is a novel protein conserved in both complex and simple eukaryotes [2]. 
Howard et al., (2001) reported this protein to early and late endosomes in African green 
monkey kidney (COS7) and human embryonic kidney (HEK) cells. It was also found to 
physically interact with SKD1/VPS4, a highly conserved protein linked to multivesicular 
body sorting in yeast. They found Chmp1 overexpression to dilate endosomal 
compartments.  Investigation of Chmp1 in HEK 293 cell line by Stauffer et al., (2001) 
also showed that when overexpressed, Chmp1 localizes to regions of condensed 
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chromatin. It recruits a polycomb group (PcG) protein to the condensed chromatin and 
can cooperate with co-expressed vertebrate PcG protein polycomblike (Pcl). In addition, 
Chmp1 has potent effects on nuclear structure and DNA replication. Their results 
suggest Chmp1 plays a role in stable gene silencing and DNA regulation. 
 Investigation from our lab showed that Chmp1 and its associated protein 
(Strabismus) produced convergent extension movement defects when overexpressed in 
zebrafish (Figure 1).  It was also observed that Chmp1 induces hyperplasia, indicating 
Chmp1 may function in tumor formation [Park et al., in preparation]. To test this 
hypothesis, human cancer profiling array was screened to measure Chmp1 mRNA 
level. Human cancer tissue array was also screened to quantify Chmp1 protein level. 
Results showed differential expression of Chmp1 between the various tumors and their 
corresponding normal tissues. Interestingly, Chmp1 mRNA level was dramatically 
down-regulated in pancreatic tumor compared to the normal tissue (Figure 2). Among 
the pancreatic cancer tissues investigated, pancreatic acinar cancer cell is the only cell 
which showed almost no expression of Chmp1 protein (Figure 3).    
The objective of this study was to investigate the molecular function of Chmp1 in 
the development of pancreatic tumors. We hypothesized that Chmp1 may function 
through retinoic acid signaling to inhibit cell growth by activating p53 in pancreatic 
cancer cells. In this study we investigated the effect of Chmp1 on the growth of 
CRL2151, a pancreatic acinar tumor cell line. Our results indicate that Chmp1 may 
function as a tumor suppressor in pancreatic tumors downstream of retinoic acid 
signaling pathway. Therefore, in addition to the reports that Chmp1 is involved in 
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nuclear gene regulation and cell cycle progression [2, 4], suggesting that it functions in 
DNA transcription and cell growth, Chmp1 may also function in tumor suppression. 
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MATERIALS AND METHODS 
Chemicals 
All-trans-Retinoic acid (ATRA) was obtained from Sigma. It was dissolved in Dimethyl 
Sulfoxide (DMSO, Fisher) at a concentration of 20µM prior to use.  
Cell line and Cell Culture Condition 
Mouse pancreatic acinar tumor cell line, CRL2151, was obtained from ATCC (America 
Type Culture Collection). Cells were maintained in HYQ Dulbecco’s Modified Eagle’s 
(DME) High glucose medium plus10% FBS and antibiotics (10000 units/ml penicillin G 
sodium and 10000 µg/ml streptomycin sulfate in 0.85% saline) at 37°C in a humidified 
atmosphere composed of 95% air and 5% CO2. 
 
Cell Transfection  
Cultured cells were harvested by trypsin digestion and seeded at 800,000cells/10cm 
plate in DME High glucose medium with 10% FBS for 24 hr. Human Chmp1 and Stbm 
genes were each previously cloned into CS2 vector containing CMV and SP6  
promoters. The constructs were named Chmp1/CS2 and Stbm/CS2. CRL2151 cells 
were transfected with 5µg of Chmp1/CS2 or Stbm/CS2 vector in a 10cm plate, using 
Lipofectamine™ Reagent (Invitrogen). Cells were also transfected with CS2 vector only. 
Both Stbm/CS2 and CS2 transfections served as controls. The transfected cells were 
incubated for 1, 2, 3 and 4 days. Photos were taken from plates daily using Leica 
DMI6000B inverted microscope attached to DFC camera to determine cell density and 
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morphology. After pictures were taken, cells were trypsinized for cell count using Phase 
Hemacytometer (Hausser Scientific). Cell lysis was done for Western blot analysis. 
 
Cell Growth Assay with ATRA treatment 
Cultured cells were harvested by trypsin digestion and seeded at 300,000cells/10cm 
plate in the DME High glucose medium with 10% FBS for 24 hr. Cell medium was 
replaced with 20µM ATRA or DMSO (control) in 10% FBS DME High glucose medium 
(1:1000), and incubated for 1, 2, 3 and 4 days. Photos were taken from plates daily 
using Leica DMI6000B inverted microscope attached to DFC camera to determine cell 
density and morphology. Thereafter, ATRA-treated and DMSO-treated plates were 
trypsinized for cell count using Phase Hemacytometer (Hausser Scientific). Cells were 
then lysed for Western blot analysis. 
Western-blot Assay  
Cells were harvested and lysed in ice-cold RIPA buffer (50mM Tris-HCl, pH 7.4, 150mM 
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 1 tablet of 
Protease Inhibitor Cocktail/ 10mL RIPA buffer. Protein expressions were quantified by 
using the BCA Protein Assay kit (EMD Biosciences, Inc. Darmstadt, Germany). Equal 
amounts of protein were loaded onto 10% SDS-polyacrylamide gels and thereafter 
blotted to an Immobilon-P membrane (Millipore, Bedford, MA). The blots were blocked 
at 4°C overnight with 5% non-fat milk in TBST (500mM Tris, 54mM KCl, 2.74 M NaCl, 
0.2% Tween-20) and subsequently incubated for 2 hr at room temperature with the 
following primary antibodies: rabbit polyclonal antibodies against human Chmp1 
(prepared and purified in our lab by Dr Natalia Belogortseva) (1 μl/ml), and stbm 
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(prepared and purified by Dr Maiyon Park) (1 μl/ml). p53 (Cell Signaling) (1 μl/ml) and 
phosphorylated-p53 (pp53) ser 37 (Cell Signaling) (1 μl/ml), Bad (Cell Signaling) (1 
μl/ml) and Bak(Cell Signaling) (1 μl/ml). A mouse MAb against β-actin (abCam) 
(0.1μl/ml) was used to confirm that the amounts of protein were equal. The blots were 
incubated for 1 hr with horseradish-peroxidase-conjugated secondary antibodies. 
Proteins were visualized by using enhanced chemiluminescent substrate detection for 
HRP (Amersham, Buckinghamshire, England). 
 
RNA Extraction and Microarray Analysis 
Total cellular RNA was prepared from cells treated with ATRA for 1 day and cells 
transfected with Chmp1 for 1 day using Tri Reagent (Sigma). In each case, cells were 
disrupted and homogenized in the Tri Reagent. Chloroform was mixed with the lysate, 
and the mixture was separated into three phases by centrifugation. The upper phase 
which contained the RNA was collected and precipitated with isopropanol. The RNA 
was used for Microarray experiment. Analysis of the results from microarray (microarray 
experiment and analysis were done by Dr. Goran Boskovic of the Genomic Core, Joan 
C. Edward School of Medicine, Marshall University) provided information on the level of 
gene expression from cells treated with ATRA and cells transfected with Chmp1. 
Differential expression of genes by microarray analysis was confirmed by Western-blot 
assay. 
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Statistical Analysis 
All statistical analyses were performed with MINITAB statistical software (version 13) for 
the Microsoft PC. Results on cell growth are expressed as mean ±SEM. Two-sample t-
test was used to compare the equality of the means of DMSO (control) and ATRA, and 
also between the means of CS2 (control) and Chmp1. 
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RESULTS 
 
Chmp1 represses growth of pancreatic tumor cells 
We investigated the effect of Chmp1 expression on the growth of cancer cells by 
transfecting CRL2151 cells with 5µg of Chmp1/ CS2 vector in a 10cm plate. Cells were 
transfected with CS2 vector and Stbm/CS2 vector to serve as control. After 1, 2, 3 or 4 
days of transfection, cells were counted and observed under Leica DMI6000B inverted 
microscope attached to DFC camera for cell morphology.  
Table 1 shows the effect of Chmp1 on the growth of CRL2151 cells. Chmp1 
inhibits the growth of the cells all through the four days of transfection when compared 
to the control (CS2 vector). However, there was no change in the morphology of the 
cells (Figure 4). 
 
 
 
Days of  Transfection 
Control 
x105 
Chmp1 
x105 
2 7.50±0.91 3.13±0.70 
3 12.50±0.91 5.00±0.72 
4 28.70±1.67 7.38±0.57 
 
Table 1: Chmp1 induces growth inhibition in Chmp1 transfected pancreatic acinar cancer cells. CRL2151 
cells were seeded at 8 x105 cells/ plate in a 10cm plate in DME High glucose medium with 10% FBS. 
After incubation for 24hr cells were transfected (in triplicate) with Chmp1/CS2 and CS2 (control) vectors. 
Cells were counted after 2, 3 and 4 days of transfection and average values from six counts were 
obtained. The t-test analysis of the difference between the means of Chmp1 and CS2 (see appendix) 
indicates a marked significant difference at 95% CI on each day, as p – values << 0.005. 
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Figure 4: Chmp1 induces growth inhibition but no morphological changes in pancreatic acinar tumor cells. 
CRL2151 cells were transfected with Chmp1/CS2 and CS2 (control) in 10cm plates for 1, 2, 3 and 4 days. 
Cell density and morphology were observed using Leica DMI6000B inverted microscope attached to DFC 
camera. Growth was inhibited in Chmp1 transfected cells (right) compared to CS2 transfected cells 
(control) (left) but no morphological changes at day 1 - 4.   
 
 
 
Day 1 
Day 4 
Day 2 
Day 3 
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Retinoic acid treatment induces the expression of Chmp1 and p53 
To investigate the effect retinoic acid has on the growth of acinar carcinoma cells, we 
counted CRL2151 cells and observed the cells under Leica DMI6000B inverted 
microscope attached to DFC camera for cell morphology after treatment with ATRA. We 
also performed Western blot analysis using antibodies which recognize Chmp1 
(25kDa), p53 (53 kDa) and Stbm (75 kDa) to investigate the expression levels of these 
proteins in the treated cells.  
The growth curve of retinoic acid-treated cells showed no decrease in growth due 
to retinoic acid treatment (Figure 5).  
Observation of these cells under microscope did not show morphological 
differences between the retinoic acid treated cells and the control treated cells (Figure 
6). This is contrary to the earlier results obtained in our lab from similar treatment on 
adinocarcinoma PanC-1 cells (Figure I). In this case, less growth was observed in 
retinoic acid treated panC-1 cells. Observation of these PanC-1 cells under microscope 
after four days of retinoic acid treatment showed less cell growth as well as 
morphological changes. 
 Treatment of CRL2151 cells with retinoic acid however showed over-expression 
of Chmp1 (4.5-fold) at day 1 compared to its expression in DMSO treated cells on the 
same day (Figure 7). Chmp1 over-expression was accompanied by up-regulation of p53 
(3.7-fold) at day 1.  Similar expression of Chmp1 and p53 was observed in Panc-1 at 
day 2 (Figures II & III). Even though stbm was over-expressed at day 4, there was no 
accompanying up-regulation of p53 (Figure 7). 
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Figure 5: Retinoic acid does not inhibit growth of pancreatic acinar tumor cells. CRL2151 cells were 
seeded at 3 x105 cells/ plate in a 10cm plate in DME High glucose medium with 10% FBS. After 
incubation for 24hr cells were treated with 20μM ATRA and DMSO (control) (in triplicate) for 1, 2, 3, and 4 
days. Cells were counted after each period of treatment. Data represent the mean ± standard errors of 
the mean (SE) from six counts. The t-test analysis of the difference between the means of DMSO and RA 
(see appendix) indicates no significant difference at 95% CI on each day.  
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Figure 6: ATRA does not induce growth inhibition or morphology change in ATRA-treated pancreatic 
acinar tumor cells. CRL2151 cells were seeded at 3 x105 cells/ plate in a 10cm plate in DME High glucose 
medium with 10% FBS. After incubation for 24hr cells were treated with 20μM ATRA and DMSO (control) 
(in triplicate) for 1, 2, 3, and 4 days. Cell density and morphology were observed using Leica DMI6000B 
inverted microscope attached to DFC camera. There was no growth inhibition in ATRA-treated cells 
(right) compared to DMSO treated cells (control) (left).No morphological changes at day 1 - 4.   
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Figure 7: CRL 2151 cells were treated with ATRA(20μM) and DMSO(control) in a 10cm plate of DME 
High glucose medium containing 10% FBS for 1, 2, 3 and 4 days. Cells were lysed, 5 micrograms of 
protein were used for Western blot and immunodetection was done for Chmp1, p53 and Stbm. Graph 
shows the expressions of Chmp1, p53 and Stbm corrected for β-actin and DMSO from densitometry 
analysis. 
 
 
 
    ATRA treatment
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Chmp1 induces the expression of p53 
CRL2151 cells were transfected with 5µg of Chmp1/ CS2 vector in a 10cm plate. Cells 
were also transfected with CS2 vector and Stbm/CS2 vector to serve as control. 
Western blot analysis was carried out using antibodies which recognize Chmp1 
(25kDa), Stbm (73 kDa), p53 (53 kDa) and pp53 (ser 37, 53 kDa). Results showed that 
the expression of Chmp1 was temporarily increased (3.7-fold) at day 1 in cells 
transfected with Chmp1/CS2 vector (Figure 8). Chmp1 over-expression was 
accompanied by p53 up regulation (3.3-fold) at day 1. This trend was followed by pp53 
(ser 37) up-regulation (3.2-fold) at day 1 too. The low expression of Chmp1 at day 2 is 
interesting, and may suggest that the expression of Chmp1 is repressed with time. 
Results from PanC-1 cell line investigated in our lab did not show Chmp1 repression 
with time. Even though Strabismus was up-regulated at day 1 and day 2 in Stbm-
transfected cells, there was no effect on p53 and pp53 protein level. This result 
demonstrates that p53 expression is specific to Chmp1 expression. 
 
Protein expression in CRL2151 cells by microarray assay 
To confirm that Chmp1 functions through retinoic acid by activating p53, microarray 
analysis was performed on cells transfected with Chmp1 for 1 day and cells treated with 
retinoic acid for 1 day. If Chmp1 functions through retinoic acid signaling we expect the 
same genes to be up or down regulated when cells are treated with retinoic acid or 
transfected with Chmp1. Table 2 shows few of same set of genes that were up or down 
regulated. Of particular interest to us is the up-regulation of Bad and Bak which promote 
apoptosis and the down regulation of cell cycle division associated proteins. Western lot 
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assay confirmed the expression of Bad and Bak genes in cells transfected with 
Chmp1/CS2 vector at day 2 and day 1 respectively (Figure 9). 
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Figure 8: CRL 2151 cells were transfected with Chmp1/CS2, Stbm/CS2 and CS2 (control) vectors in a 
10cm plate of DME High glucose medium containing 10% FBS for 1 and 2 days. Cells were lysed for 
Western blot with immunodetection for Chmp1, p53, pp53 (ser37) and Stbm. Graphs show the 
expressions of Chmp1, p53, pp53 and Stbm corrected for β-actin and CS2 from densitometry analysis.  
    Stbm transfection      Chmp1 transfection 
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UP Regulated Down Regulated 
 
Official 
Symbol 
 
Gene 
ID 
 
Name 
Function 
(Expression 
Fold) 
 
Official 
Symbol 
 
Gene 
ID 
 
Name 
Function 
(Expression 
Fold) 
 
Bak1 
 
12018  
 
Bcl2-
antagonist 
 
Proapoptotic 
(2) 
 
Sfrs1 
 
110809 
Splicing factor, 
arginine/serine-
rich1 
Splicing of 
pre-mRNA  
(2) 
 
Bad 
 
12015 
Bcl-
associated 
death 
promoter 
 
Proapoptotic 
(2) 
 
Cdca7 
 
66953 
 
Cell division cycle 
associated 7 
Overexpress
ed in human 
tumors (2.5) 
 
 
Slc9a8 
 
77031 
 
Solute carrier 
family 
Control of 
intracellular 
pH (2) 
 
Rpl22 
 
19934 
 
Ribosomal 
protein L22 
Regulation of 
protein 
synthesis (3) 
 
Prrx1 
 
18933 
Paired 
related 
homeobox1 
 Cranial 
development 
(2) 
 
Vbp1 
 
22327 
Von Hippel-
Lindau binding 
protein 1 
Tumor 
suppressor 
gene (2) 
 
Barx2 
 
12023 
 
BarH-like 
homeobox2 
 
Cellular 
differentiation 
(34) 
 
Oazin 
or Oazi 
 
 
54375 
 
Ornithine 
decarboxylase 
antizyme inhibitor 
Tumor 
inducer, cell 
growth and 
division (2) 
     
Hnrpab 
 
15384 
Heterogenous 
nuclear 
ribonucleo 
protein A/B 
 
RNA splicing, 
transport (3) 
 
Table 2: Microarray results of total mRNA from CRL 2151 cells transfected with Chmp1 for I day and cells 
treated with ATRA for I day. After treatment with retinoic acid or transfection with Chmp1/CS2, RNA was 
made using the Tri reagent. cDNA was generated and hybridized to agilent whole genome mouse 44k 
array for analysis. Genes in the table are expressed in transfected and treated cells.  
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Figure 9:  Chmp1 induces the expression of Bcl-2 family. CRL 2151 cells were transfected with 
Chmp1/CS2, Stbm/CS2 and CS2 (control) vectors in a 10cm plate of DME High glucose medium 
contining10% FBS for 1 and 2 days. Cells were lysed for Western blot with immunodetection for Bad and 
Bak. Graph shows the expressions of Bad and Bak corrected for β-actin and CS2 from densitometry 
analysis. 
    Chmp1 transfection
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DISCUSSION 
 
The present study has led to a new finding about Chmp1 function in the suppression of 
pancreatic tumor through the retinoic acid pathway. Chmp1 is thought to play a role in 
the regulation of gene expression when located in the nucleus [2-4]. It was also 
observed that when zebrafish embryos were microinjected with Chmp1, it induced 
hyperplasia. On the basis of this observation and our results from the human cancer 
profiling array for Chmp1, it is possible that Chmp1 may be involved in suppressing the 
growth of tumor cells. We therefore hypothesized that Chmp1 may play a role in 
inhibiting cell growth through retinoic acid signaling by activating p53. Protein p53 is 
reported to be expressed and regulate cell growth and apoptosis during cancer cell 
growth inhibition [35]. In this study we have shown that exogenous Chmp1 indeed 
resulted in the inhibition of growth (Table 1) however, without any morphological change 
of cells (Figure 4).  
Retinoids are therapeutically used in the treatment of some cancers [31]. They 
are reported to cause a decrease in the number of cells in pancreatic cancer [9, 16-17]. 
Results from our study did not show decrease in the growth of cells due to retinoic acid 
treatment. This result is not surprising. A similar result was reported by Rosewicz et al 
(1995), in which pancreatic acinar tumor cells did not show growth inhibition after 
treatment with retinoids. Furthermore, Fujimoto et al (1999) reported that some 
pancreatic tumor cell lines did not show growth inhibition when treated with retinoids. 
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It is not known if Chmp1 expression is induced by retinoic acid treatment, nor 
what function it may carryout if expressed. In this study, our result was able to show that 
retinoic acid treatment induced the over-expression of Chmp1. This over-expression of 
Chmp1 was accompanied by the up regulation of p53. Our further investigation showed 
expression of Chmp1, p53 and pp53 (ser 37) to be up-regulated in cells transfected with 
Chmp1 (Figure 8), accompanied by growth inhibition. Taken together, these results 
suggest that Chmp1 inhibits cell growth by inducing the activation of p53 through RA 
signaling pathway.  
 Strabismus, a binding partner of Chmp1 from the yeast 2-hybrid screening 
carried out in our lab, was up-regulated at day 1 and day 2. However, it did not show 
effect on p53 and pp53 protein level. This observation shows that even though 
Strabismus functions in vertebrate extension movement, the induction of hyperplasia 
and tumor suppression is rather specific to Chmp1 expression.  
Microarray analysis of cells treated with ATRA and cells transfected with Chmp1 
showed up-regulation of Bad and Bak (pro-apoptosis proteins), in addition to other 
proteins up-regulated. Cell division cycle associated protein 7 (Cdca7) was among 
proteins down-regulated. Cdca7 is frequently over-expressed in human cancers[74]. 
The down-regulation of Cdca7 and up-regulation of Bad and Bak in our study further 
supports the suggestion that Chmp1 is involved in growth inhibition of CRL2151 cells, 
consequently functioning in suppressing cancer growth.  
In summary, the results from this study have shown that Chmp1 induces growth 
inhibition in pancreatic tumor. Its expression is induced by retinoic acid in retinoic acid 
treated pancreatic acinar tumor cells. Microarray analysis showed similar genes to be 
 40 
 
 
up or down regulated in cells treated with retinoic acid and cells transfected with 
Chmp1.     
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CHAPTER 4 
CONCLUSIONS 
1. Chmp1 was found to induce growth inhibition but no morphological changes when 
CRL 2151 cells were transfected with Chmp1.  
2. Over-expression of Chmp1 was induced in ATRA-treated cells accompanied by the 
up-regulation of p53. 
3. Chmp1 induced the up-regulation of p53 and also induced its stability by the up-
regulation of pp53-ser 37 in Chmp1-transfected CRL 2151 cells. Strabismus did not 
show effect on p53 and pp53-ser 37 protein levels. 
4. Similar proteins were up-regulated or down-regulated when CRL2151 cells were 
treated with ATRA and transfected with Chmp1. Apoptotic agonists, Bad and Bak, were 
among proteins up-regulated. 
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FUTURE DIRECTIONS 
Future direction on this study will focus on confirming other up and down regulated 
genes from microarray analysis of cells transfected with Chmp1 and cells treated with 
retinoic acid. This will include confirming Bad and Bak in RA treated cells. 
Since our results showed that p53 and pp53 expression accompanied the 
expression of Chmp1, investigating upstream proteins in p53 pathway (e.g. DNA-PK, 
ATM) will provide information whether activated p53 induces growth arrest or apoptosis 
or both during cell growth inhibition. This will be carried out by Western blot analysis of 
lysate from CRL2151 cells transfected with Chmp1. Test for apoptosis will be done 
using e.g. Tunel assay, Serine assay or Caspase detection assay.  Also Chmp1 
transfection efficiency using the GFP cotransfection method will be determined. 
We will further investigate the functions of Chmp1 by siRNA silencing of Chmp1 
gene in CRL2151 cells. This will include studying the expression levels of p53 and pp53 
after Chmp1 knock down in the cells. 
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 APPENDIX 
 
 
 
Figure I: Treatment of panc-1 cells with ATRA (10μM) inhibits growth and results in morphology changes. 
A- growth curve of panc-1 treated with ATRA. B- changes in cell morphology observed under Leica 
inverted microscope attached to DFC camera. (Courtesy of Brandon Orr). 
---■---■---■--- RA; ---♦---♦---♦--- DMSO 
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Figure II: Western blot of panc-1 cells after treatment with 20μM ATRA. L- Low confluency. H- High 
confluency (Courtesy of Brandon Orr).   
 
 
Figure III: Western blot of panc-1 cells after treatment with 20μM ATRA (Courtesy of Brandon Orr).   
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Raw data 
 
Raw data table for ATRA treated growth curve. 
 
 
Day Day1 Day1 Day2 Day2 Day3 Day3 Day4 Day4 
Treatment DMSO RA DMSO RA DMSO RA DMSO RA 
Raw Data 2.50E+05 1.25E+05 5.00E+05 5.00E+05 7.00E+05 6.25E+05 2.00E+06 2.50E+06 
 2.20E+05 3.50E+05 2.75E+05 2.50E+05 1.00E+06 6.25E+05 2.50E+06 2.75E+06 
 3.75E+05 1.25E+05 3.75E+05 3.75E+05 5.00E+05 8.75E+05 2.63E+06 2.00E+06 
 2.50E+05 2.50E+05 6.75E+05 6.23E+05 8.75E+05 1.25E+06 2.25E+06 2.63E+06 
 2.50E+05 2.50E+05 1.25E+05 1.25E+05 8.75E+05 6.25E+05 3.13E+06 3.00E+06 
 1.25E+05 2.50E+05 3.75E+05 2.50E+05 1.38E+06 5.00E+05 3.63E+06 2.88E+06 
         
Mean  2.45E+05 2.25E+05 3.88E+05 3.54E+05 8.88E+05 7.50E+05 2.69E+06 2.63E+06 
Standard Error of the mean 3.27E+04 3.54E+04 7.69E+04 7.49E+04 1.21E+05 1.12E+05 2.43E+05 1.44E+05 
Standard Deviation 8.00E+04 8.66E+04 1.88E+05 1.83E+05 2.95E+05 2.74E+05 5.96E+05 3.54E+05 
Count 6 6 6 6 6 6 6 6 
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Two-Sample T-Test for DMSO and RA (Day1)  
 
    N      Mean     StDev   SE Mean 
DMSO    6    245000     80000     32660 
RA         6    225000     86603     35355 
 
Difference = µ DMSO - µ RA 
Estimate for difference:  20000 
95% CI for difference: (-88882, 128882) 
T-Test of difference = 0 (vs. not =): T-Value = 0.42 P-Value = 0.687 DF = 10 
 
 
 
Two-Sample T-Test for DMSO and RA (Day2)  
 
            N      Mean     StDev   SE Mean 
DMSO       6    387500    188249     76852 
RA         6    353833    183407     74876 
 
Difference = µ DMSO - µ RA 
Estimate for difference:  33667 
95% CI for difference: (-209056, 276389) 
T-Test of difference = 0 (vs. not =): T-Value = 0.31 P-Value = 0.761 DF = 10 
 
 
Two-Sample T-Test for DMSO and RA (Day3)  
 
           N      Mean     StDev   SE Mean 
DMSO     6    887500    295275    120546 
RA       6    750000    273861    111803 
 
Difference = µ DMSO - µ RA 
Estimate for difference:  137500 
95% CI for difference: (-234425, 509425) 
T-Test of difference = 0 (vs. not =): T-Value = 0.84 P-Value = 0.425 DF = 10 
 
 
Two-Sample T-Test for DMSO and RA (Day4)  
  
            N      Mean     StDev   SE Mean 
DMSO       6   2687500    595556    243135 
RA         6   2625000    353553    144338 
 
Difference = µ DMSO - µ RA 
Estimate for difference:  62500 
95% CI for difference: (-589524, 714524) 
T-Test of difference = 0 (vs. not =): T-Value = 0.22 P-Value = 0.831 DF = 10 
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Raw data 
 
Raw data table for Chmp1 transfected growth curve. 
 
 
 
Day Day2 Day2 Day3 Day3 Day4 Day4 
Vector CS2 Chmp1 CS2 Chmp1 CS2 Chmp1 
Raw data 6.25E+05 2.50E+05 1.38E+06 3.75E+05 3.50E+06 8.75E+05 
 3.75E+05 2.50E+05 1.13E+06 2.50E+05 2.88E+06 7.50E+05 
 7.50E+05 3.75E+05 8.75E+05 5.00E+05 2.88E+06 7.50E+05 
 8.75E+05 6.25E+05 1.25E+06 6.25E+05 2.38E+06 5.00E+05 
 8.75E+05 1.25E+05 1.38E+06 7.50E+05 3.10E+06 6.75E+05 
 1.00E+06 2.50E+05 1.50E+06 5.00E+05 2.50E+06 8.75E+05 
       
Mean 7.50E+05 3.13E+05 1.25E+06 5.00E+05 2.87E+06 7.38E+05 
Standard Error of the mean 9.13E+04 7.03E+04 9.13E+04 7.22E+04 1.67E+05 5.73E+04 
Standard Deviation 2.24E+05 1.72E+05 2.24E+05 1.77E+05 4.08E+05 1.40E+05 
Count 6 6 6 6 6 6 
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Two-Sample T-Test for CS2 and Chmp1 (Day2) 
 
 
            N      Mean     StDev   SE Mean 
CS2        6    750000    223607     91287 
Chmp1      6    312500    172301     70341 
 
Difference = µ CS2 - µ Chmp1 
Estimate for difference:  437500 
95% CI for difference: (176799, 698201) 
T-Test of difference = 0 (vs. not =): T-Value = 3.80 P-Value = 0.004 DF = 10 
 
 
 
Two-Sample T-Test for CS2 and Chmp1 (Day3) 
 
 
            N      Mean     StDev   SE Mean 
CS2        6   1252500    224182     91522 
Chmp1      6    500000    176777     72169 
 
Difference = µ CS2 - µ Chmp1 
Estimate for difference:  752500 
95% CI for difference: (488839, 1016161) 
T-Test of difference = 0 (vs. not =): T-Value = 6.46 P-Value = 0.000 DF = 10 
 
 
 
Two-Sample T-Test for CS2 and Chmp1 (Day4) 
 
 
            N      Mean     StDev   SE Mean 
CS2        6   2873333    406678    166025 
Chmp1      6    737500    140312     57282 
 
Difference = µ CS2 - µ Chmp1 
Estimate for difference:  2135833 
95% CI for difference: (1705965, 2565702) 
T-Test of difference = 0 (vs. not =): T-Value = 12.16 P-Value = 0.000 DF = 10 
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Film properties report for Chmp1 (transfected) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody: Chmp1                      Dilution: 1: 1000       Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Rabbit            Dilution: 1: 1000       Medium: 5% milk in TBS-T 
 
Molecular weight: 25 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: CS2 Day1 
 
Lane 3: Chmp1 Day1 
 
Lane 4: Stbm Day1 
 
Lane 5: CS2 Day2 
 
Lane 6: Chmp1 Day2 
 
Lane 7: Stbm Day2 
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Film properties report for Chmp1-βactin (transfected) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody:  β-actin (abCam)               Dilution: 1: 10000       Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Mouse            Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Molecular weight: 42 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: CS2 Day1 
 
Lane 3: Chmp1 Day1 
 
Lane 4: Stbm Day1 
 
Lane 5: CS2 Day2 
 
Lane 6: Chmp1 Day2 
 
Lane 7: Stbm Day2 
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Raw data table produced from spot densitometry of Western blot films. 
                                                            Chmp1-Transfected 
 Adj. Vol. INT    
Trf-Chmp Trf-Chmpactin 
Trf-
Chmp(ratio) Trf-Chmp(corr) 
2149.88 1409.27 1.525527401 1 
5611.76 982.58 5.711249975 3.743787212 
2905.17 2977.67 0.975652104 0.639550691 
2925.06 5940.36 0.492404501 1 
1619.69 7128.46 0.227214574 0.461438864 
735.05 6746.6 0.108951175 0.221263565 
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Film properties report for Stbm (transfected) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody: StbmN                     Dilution: 1: 1000      Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Rabbit           Dilution: 1: 1000      Medium: 5% milk in TBS-T 
 
Molecular weight: 75 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: CS2 Day1 
 
Lane 3: Chmp1 Day1 
 
Lane 4: Stbm Day1 
 
Lane 5: CS2 Day2 
 
Lane 6: Chmp1 Day2 
 
Lane 7: Stbm Day2 
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Film properties report for Stbm- βactin (transfected) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody:  β-actin (abCam)                Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Mouse         Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Molecular weight: 42 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: CS2 Day1 
 
Lane 3: Chmp1 Day1 
 
Lane 4: Stbm Day1 
 
Lane 5: CS2 Day2 
 
Lane 6: Chmp1 Day2 
 
Lane 7: Stbm Day2 
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Raw data table produced from spot densitometry of Western blot films. 
                                                             Strabismus-Transfected 
           Adj. Vol. INT   
Trf-Stbm Trf-Stbmactin Trf-Stbm(ratio) Trf-Stbm(corr) 
1337.14 15658.81 0.09 1.0 
1928.95 14340.55 0.13 1.6 
1531.08 7863.4 0.19 2.3 
666.47 2578.45 0.26 1.0 
917.46 6110.94 0.15 0.6 
4729.11 6682.03 0.71 2.7 
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Film properties report for p53 (transfected) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody:  p53 (Cell Signaling)         Dilution: 1: 1000       Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Rabbit            Dilution: 1: 1000      Medium: 5% milk in TBS-T 
 
Molecular weight: 53 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: CS2 Day1 
 
Lane 3: Chmp1 Day1 
 
Lane 4: Stbm Day1 
 
Lane 5: CS2 Day2 
 
Lane 6: Chmp1 Day2 
 
Lane 7: Stbm Day2 
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Film properties report for p53- βactin (transfected) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody:  β-actin (abCam)               Dilution: 1: 10000       Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Mouse            Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Molecular weight: 42 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: CS2 Day1 
 
Lane 3: Chmp1 Day1 
 
Lane 4: Stbm Day1 
 
Lane 5: CS2 Day2 
 
Lane 6: Chmp1 Day2 
 
Lane 7: Stbm Day2 
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Raw data table produced from spot densitometry of Western blot films. 
P53-Transfected 
Adj. Vol. INT    
Trf-p53 Trf-p53actin Trf-p53(ratio) Trf-p53(corr) 
4173.25 7083.78 0.59 1.00 
8404.02 4309.6 1.95 3.31 
3018.73 2802.82 1.07 1.82 
2939.58 4804.18 0.61 1.00 
2916.19 5010.87 0.58 0.95 
3323.25 5365.64 0.62 1.01 
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Film properties report for phosphor p53- ser 37 (transfected) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody: pp53-ser 37 (Cell Signaling)   Dilution: 1: 1000   Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Rabbit            Dilution: 1: 1000      Medium: 5% milk in TBS-T 
 
Molecular weight: 53 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: CS2 Day1 
 
Lane 3: Chmp1 Day1 
 
Lane 4: Stbm Day1 
 
Lane 5: CS2 Day2 
 
Lane 6: Chmp1 Day2 
 
Lane 7: Stbm Day2 
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Film properties report for pp53 ser37-βactin (transfected) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody:  β-actin (abCam)               Dilution: 1: 10000       Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Mouse            Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Molecular weight: 42 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: CS2 Day1 
 
Lane 3: Chmp1 Day1 
 
Lane 4: Stbm Day1 
 
Lane 5: CS2 Day2 
 
Lane 6: Chmp1 Day2 
 
Lane 7: Stbm Day2 
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Raw data table produced from spot densitometry of Western blot films. 
                                                          Pp53 (ser 37)-Transfected 
Adj. Vol. INT    
Trf-ser37 Trf-ser37-actin Trf-ser37(ratio) Trf-ser37(corr) 
4713.86 1409.27 3.344894875 1 
10634.81 982.58 10.82335281 3.235782651 
7871.56 2977.67 2.643530008 0.790317815 
11386.88 5940.36 1.916866991 1 
13476.64 7128.46 1.890540173 0.986265704 
12789.99 6746.6 1.895768239 0.988993106 
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Film properties report for Chmp1 (ATRA treated) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody: Chmp1                     Dilution: 1: 1000       Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Rabbit          Dilution: 1: 1000       Medium: 5% milk in TBS-T 
 
Molecular weight: 25 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: RA Day1 
 
Lane 3: DMSO Day1 
 
Lane 4: RA Day2 
 
Lane 5: DMSO Day2 
 
Lane 6: RA Day3 
 
Lane 7: DMSO Day3 
 
Lane 8: RA Day4 
 
Lane 9: DMSO Day4 
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Film properties report for Chmp1-βactin (ATRA treated) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody:  β-actin (abCam)               Dilution: 1: 10000       Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Mouse            Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Molecular weight: 42 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: RA Day1 
 
Lane 3: DMSO Day1 
 
Lane 4: RA Day2 
 
Lane 5: DMSO Day2 
 
Lane 6: RA Day3 
 
Lane 7: DMSO Day3 
 
Lane 8: RA Day4 
 
Lane 9: DMSO Day4 
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Raw data table produced from spot densitometry of Western blot films. 
                                                          Chmp1-ATRA treated 
Adj. Vol. INT    
Trd-Chmp Trd-Chmp-actin Trd-Chmp(ratio) Trd-Chmp(corr) 
2056.11 14398.49 0.142800391 1.0 
7115.64 11045.35 0.644220419 4.5 
2535.09 13516.78 0.187551325 1.0 
799.37 11778.02 0.067869642 0.4 
372.59 13409.67 0.027785173 1.0 
1563.17 13207.32 0.118356336 4.3 
2785.21 16080.38 0.173205484 1.0 
3593.7 16593.57 0.216571841 1.3 
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Film properties report for Stbm (ATRA treated) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody:  StbmN              Dilution: 1: 1000       Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Rabbit            Dilution: 1: 1000      Medium: 5% milk in TBS-T 
 
Molecular weight: 75 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: RA Day2 
 
Lane 3: DMSO Day2 
 
Lane 4: RA Day3 
 
Lane 5: DMSO Day3 
 
Lane 6: RA Day4 
 
Lane 7: DMSO Day4 
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Film properties report for Stbm - βactin (ATRA treated) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody:  β-actin (abCam)               Dilution: 1: 10000       Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Mouse            Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Molecular weight: 42 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: RA Day2 
 
Lane 3: DMSO Day2 
 
Lane 4: RA Day3 
 
Lane 5: DMSO Day3 
 
Lane 6: RA Day4 
 
Lane 7: DMSO Day4 
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Raw data table produced from spot densitometry of Western blot films. 
 
                                                       Strabismus-ATRA treated 
 
 
Adj. Vol. INT    
Trd-Stbm Trd-Stbmactin Trd-Stbm(ratio) Trd-Stbm(corr) 
3533.43 16231.67 0.217687398 1.0 
5728.83 17223.41 0.332618802 1.5 
645.07 17457.64 0.036950584 1.0 
1458.15 18362.55 0.079408906 2.1 
811.84 21005.89 0.038648208 1.0 
2984.38 16673.09 0.178993816 4.6 
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Film properties report for p53 (ATRA treated) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody:  p53 (Cell Signaling)         Dilution: 1: 1000       Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Rabbit            Dilution: 1: 1000      Medium: 5% milk in TBS-T 
 
Molecular weight: 53 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: RA Day1 
 
Lane 3: DMSO Day1 
 
Lane 4: RA Day2 
 
Lane 5: DMSO Day2 
 
Lane 6: RA Day3 
 
Lane 7: DMSO Day3 
 
Lane 8: RA Day4 
 
Lane 9:  DMSO Day4 
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Film properties report for p53- βactin (ATRA treated) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody: β-actin (abCam)         Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Rabbit            Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Molecular weight: 42 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: RA Day1 
 
Lane 3: DMSO Day1 
 
Lane 4: RA Day2 
 
Lane 5: DMSO Day2 
 
Lane 6: RA Day3 
 
Lane 7: DMSO Day3 
 
Lane 8: RA Day4 
 
Lane 9:  DMSO Day4 
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Raw data table produced from spot densitometry of Western blot films. 
 
                                                           p53-ATRA treated 
 
 
Adj. Vol. INT    
Trd-p53 Trd-p53actin Trd-p53(ratio) Trd-p53(corr) 
1794.39 14398.49 0.12462348 1.0 
5120.17 11045.35 0.46355887 3.7 
3065.98 13516.78 0.22682769 1.0 
2802.92 11778.02 0.23797888 1.0 
2292.13 13409.67 0.17093113 1.0 
2903.23 13207.32 0.21981977 1.3 
3582.19 16080.38 0.22276775 1.0 
4262.39 16593.57 0.25686998 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 75 
 
 
Film properties report for BAD (transfected) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody: BAD (Cell Signaling)         Dilution: 1: 1000       Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Rabbit            Dilution: 1: 1000       Medium: 5% milk in TBS-T 
 
Molecular weight: 23 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: CS2 Day1 
 
Lane 3: Chmp1 Day1 
 
Lane 4: Stbm Day1 
 
Lane 5: CS2 Day2 
 
Lane 6: Chmp1 Day2 
 
Lane 7: Stbm Day2 
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Film properties report for BAD- βactin (transfected) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody:  β-actin (abCam)                Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Mouse         Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Molecular weight: 42 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: CS2 Day1 
 
Lane 3: Chmp1 Day1 
 
Lane 4: Stbm Day1 
 
Lane 5: CS2 Day2 
 
Lane 6: Chmp1 Day2 
 
Lane 7: Stbm Day2 
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Raw data table produced from spot densitometry of Western blot films. 
 
                                                                Bad-Transfected 
 
 
Adj. Vol. INT    
Trf-Bad Trf-Badactin Trf-Bad(ratio) Trf-Bad(corr) 
0 12592.14 0 0.0 
0.4588 9495.77 4.83163E-05 0.0 
0 6162.74 0 0.0 
1780.23 8879 0.20049893 1.0 
9472.59 6137.55 1.543382946 7.7 
8651.35 3726.98 2.321276208 11.6 
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Film properties report for BAK (transfected) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody: BAD (Cell Signaling)         Dilution: 1: 1000       Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Rabbit            Dilution: 1: 1000       Medium: 5% milk in TBS-T 
 
Molecular weight: 25 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: CS2 Day1 
 
Lane 3: Chmp1 Day1 
 
Lane 4: Stbm Day1 
 
Lane 5: CS2 Day2 
 
Lane 6: Chmp1 Day2 
 
Lane 7: Stbm Day2 
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Film properties report for BAK- βactin (transfected) 
 
Cell type: CRL 2151                            Protein quantity: 5μg 
 
Gel type: 10% Tris-HCL SDSPAGE    Electrophoresis Voltage: 100V     
 
Transfer Voltage: 100V                         Duration: 45min 
 
Primary Antibody:  β-actin (abCam)                Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Secondary Antibody: Anti Mouse         Dilution: 1: 10000      Medium: 5% milk in TBS-T 
 
Molecular weight: 42 kDa 
 
Lane 1: ProSieve color protein marker 5μl 
 
Lane 2: CS2 Day1 
 
Lane 3: Chmp1 Day1 
 
Lane 4: Stbm Day1 
 
Lane 5: CS2 Day2 
 
Lane 6: Chmp1 Day2 
 
Lane 7: Stbm Day2 
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Raw data table produced from spot densitometry of Western blot films. 
 
                                                              Bak-Transfected 
 
 
Adj. Vol. INT    
Trf-Bak Trf-Bak-actin Trf-Bak(ratio) Trf-Bak(corr) 
2324.67 11910.45 0.19517902 1.0 
5273.09 10221.44 0.51588524 2.6 
4044.86 9292.91 0.43526301 2.2 
1190.51 12478.32 0.09540627 1.0 
698.66 14475.16 0.04826613 0.5 
1711.21 11878.11 0.14406417 1.5 
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